The negative trailing P/E of -243.92 is not meaningful on its own, so the forward multiples and EV/EBITDA of 169.65 falling to 81.28 forward carry more analytical weight. Compared with the peer group, where P/B is 18.90 for iRhythm and 4.35 for Novocure, ATRC's 5.68 P/B looks less stretched, suggesting investors are paying for asset quality and clinical moat rather than earnings. The valuation therefore appears to hinge on whether recent margin improvement persists rather than on current profitability.

The stable gross margin points to durable pricing on specialized single-use devices, but the operating margin trajectory is the more informative signal for earning power. The Q2 2026 peak appears partly quarter-dependent, since Q3 2026 net margin fell to 2.6 percent, which warrants monitoring before treating the turn as sustained. Stock-based compensation of roughly $11 to $12 million per quarter likely accounts for a meaningful share of the gap between reported and economic profitability.

The move from negative to modestly positive returns reflects operating leverage rather than any change in capital efficiency, as asset turnover has held flat near 0.22 across the period. Returns are still far below any reasonable cost of capital, so the company has not yet demonstrated that incremental invested capital earns an adequate return. Investors should monitor whether ROIC can sustain a multi-quarter trend above zero.

Low absolute leverage limits refinancing exposure, and the balance sheet does not appear to be the binding constraint on the equity story. Coverage ratios that were negative for most of the period reflect operating losses rather than debt burden, and the recent positive readings are not yet a durable track record. Based on reported figures, the risk is less about debt service and more about whether operating income stays positive long enough to make coverage meaningful.